Results 101 to 110 of about 3,775 (204)

A Review of Therapies for Clostridioides difficile Infection

Antibiotics
Clostridioides difficile is an urgent public health threat that affects approximately half a million patients annually in the United States. Despite concerted efforts aimed at the prevention of Clostridioides difficile infection (CDI), it remains a ...
Faiza Morado, Neha Nanda
doaj   +1 more source

Switching Residues: A Platform for the Synthesis of Fidaxomicin Antibiotics

Angewandte Chemie International Edition
AbstractPeripheral modification is often the main approach to optimize natural products for improved biological activity or desired physicochemical properties. This procedure inevitably increases molecular weight, often accompanied by undesired increased lipophilicity. Removing structural elements from natural products is not always tolerated.
Erik Jung, Tizian Griesser, Jordan Costafrolaz, Ondine Duverger, Yves Mattenberger, Silvia Dittmann, Andrea Dorst, Alexander Major, David Dailler, Daniel Schäfle, Susanne Sievers, Konstantin Brodolin, Patrick H. Viollier, Peter Sander, Karl Gademann   +14 more
openaire   +3 more sources

Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials.

, 2012
peer reviewedTwo recently completed phase 3 trials (003 and 004) showed fidaxomicin to be noninferior to vancomycin for curing Clostridium difficile infection (CDI) and superior for reducing CDI recurrences.
Stoesser, Nicole E., A Sarah Walker (9251970), Kean, Y, Walker, A Sarah, Stoesser, Nicole E, Weiss, K, Miller, MA, Sherwood L Gorbach (16235663), Peto, Timothy E A, Stoesser, NE, Mark A Miller (15241241), Peto, Timothy E. A., Angus, Brian J, Miller, Mark A., Gorbach, Sherwood L, Walker, AS, Crook, Derrick W., Derrick W Crook (9552821), Yin Kean (16235648), Young, BC, Roberto Esposito (139969), Bernadette C Young (16235657), Gorbach, Sherwood L., Angus, Brian, Louie, TJ, Jacobs, Frédérique, Crook, DW, Angus, BJ, Brian J Angus (16235660), Cornely, Oliver A, Kean, Yin, Crook, Derrick W, Walker, Ann, Nicole E Stoesser (16235654), Timothy E A Peto (16039838), Young, Bernadette C, Martin Llewelyn (4461757), Cornely, Oliver A., et al the Optimer Study 003/004 teams (16235666), Peto, TE, Esposito, R, Louie, Thomas J, Walker, A. Sarah, Karl Weiss (471420), Esposito, Roberto, Miller, Mark A, Weiss, Karl, Young, Bernadette C., Louie, Thomas J., Angus, Brian J., Thomas J Louie (16235651), Gorbach, SL, Oliver A Cornely (16234868), Cornely, OA   +53 more
core   +1 more source

Clostridioides difficile infection in hospital and community settings: summary document of a multidisciplinary group

Italian Journal of Medicine
Clostridioides difficile infection (CDI) affects the majority of hospital wards. In the context of a Continuing Medical Education Field Training course, a multidisciplinary group of expert healthcare professionals addressed the issue of CDI, producing a
Anna Danise, Federica Furfaro, Gianni Gattuso, Nicola Lucio Liberato, Clara Mandelli, Giuseppe Mazzola, Bianca Osnaghi   +6 more
doaj   +1 more source

Efficacy of alternative fidaxomicin dosing regimens for treatment of simulated Clostridium difficile infection in an in vitro human gut model

, 2015
Background: Fidaxomicin treatment reduces the risk of recurrent Clostridium difficile infection (CDI) compared with vancomycin. Extending duration of fidaxomicin therapy may further reduce recurrence. We compared the efficacy of four extended fidaxomicin
Longshaw, CM, Chilton, CH, Ashwin, H, Karas, A, Todhunter, SL, Wilcox, MH, Crowther, G   +6 more
core   +1 more source

Fidaxomicin [PDF]

Drugs in R & D, 2010
openaire   +1 more source

Comparative effectiveness of vancomycin and fidaxomicin in the treatment of Clostridioides difficile-associated diarrhea: A single-center experience in Taiwan. [PDF]

Medicine (Baltimore)
Tseng WC, Chen KC, Chung CS, Tseng PC, Lin CK, Liao CH.   +5 more
europepmc   +1 more source

Fidaxomicin [PDF]

, 2020
openaire   +1 more source

Fidaxomicin for Clostridiodes difficile infection in inflammatory bowel disease: a multicenter retrospective cohort study

Inflammatory bowel disease (IBD) patients with Clostridiodes difficile Infection (CDI) are at increased risk of disease exacerbations, therapy escalation, colectomy, and mortality. Data on fidaxomicin use in IBD patients with CDI are very limited.
Macaluso, F., Iglesias, R. Ferreiro, Tettoni, E., Zilli, A., Gheorghe, C., Rath, T., Saibeni, S., Dragoni, G., Innocenti, T., Acosta, M. Barreiro-de, Barberio, B., Savarino, E. V., Gisbert, J. P., Bezzio, C., Losco, A., Viganò, C., Cohen, M. Kornowski, Yanai, H., Gabrielli, A. M. Carvalhas, Conforti, F. S., Bossuyt, P., Caprioli, F., Blesl, A., Calderone, S., Chaparro, M., Vieujean, S., Pirola, L., Noviello, D., Atreya, R., Oliveira, R. F. de, Vecchi, M., Molnár, T.   +31 more
core   +1 more source

Effectiveness of fidaxomicin in preventing recurrence after initial community-associated <i>Clostridioides difficile</i> infection. [PDF]

Antimicrob Steward Healthc Epidemiol
Hawco A, Myers C, Dahhan R, Hurley C, van Wijngaarden E, Felsen C, Dumyati G.   +6 more
europepmc   +1 more source